Skip to main content
  • Home
  • Affected by Cancer
  • Healthy living
  • Clinical best practice
  • Research & Data
  • Publications & Resources
  • About us
  • Publications & Resources
  • Publications & Resources
  • Shared follow-up care

More at Cancer Australia

Australian Government - Cancer Australia
Home

CANCER AUSTRALIA STATEMENTS

  • Home
  • Breast cancer
  • Metastatic breast cancer

Practice 10

  • Home
  • Home
  • About the Statement
  • How the Statement was developed
  • The 12 Practices
  • Consumer Fact Sheets
  • mobile menu
  • Home
  • Home
  • About the Statement
  • How the Statement was developed
  • The 12 Practices
  • Consumer Fact Sheets
  • Home
  • Breast cancer
  • Metastatic breast cancer
  • Home
  • Home
  • How the Statement was developed
  • The 10 practices
  • Consumer Fact Sheets
  1. The 12 Practices
  2. Practice 10
  • A|A

Practice 10

Not appropriate to offer a sentinel node biopsy to patients diagnosed with DCIS (ductal carcinoma in situ) having breast conserving surgery, unless clinically indicated.

Consumer Information
Sentinel node biopsy
DCIS
breast conserving surgery

Sentinel node biopsy for DCIS

Download the transcript (DOCX 48.99 KB)

Context

DCIS (ductal carcinoma in situ) is a non-invasive breast cancer where the abnormal cells are contained within the milk ducts of the breast.  In 2016, it is estimated that there will be approximately 2,090 new cases of DCIS in Australia.

Evidence from several studies has shown that the risk of someone diagnosed with DCIS having spread of their disease to other parts of the breast or other parts of the body, is very low.  This means that for most patients diagnosed with DCIS, procedures aimed at determining if breast cancer has spread beyond the breast, such as sentinel node biopsy, are unnecessary. 

International guidelines recommend that patients with DCIS having breast conserving surgery should only undergo a sentinel node biopsy if they are considered to have a high risk of invasive disease.  Clinical indications of high risk include high grade DCIS, extensive disease, or a palpable mass.  

Value to patients

Unnecessary invasive procedures, such as sentinel node biopsy can lead to harm through over-treatment, risk of post-surgical complications, side effects and unnecessary anxiety.  

Supporting evidence

Australian Institute of Health and Welfare 2015. Breast cancer in young women: key facts about breast cancer in women in their 20s and 30s. Cancer series no. 96. Cat. no. CAN 94. Canberra: AIHW.

Francis AM, Haugen CE, Grimes LM et al. Is sentinel lymph node dissection warranted for patients with a diagnosis of ductal carcinoma in situ? Annals of Surgical Oncology. 2015;22(13):4270-9.

Intra M, Rotmensz N, Veronesi P, et al. Sentinel node biopsy is not a standard procedure in ductal carcinoma in situ of the breast: the experience of the European Institute of Oncology on 854 patients in 10 years. Annals of Surgery. 2008;247(2):315–319.

Lyman GH, Temin S, Edge SB et al. Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update. Journal of Clinical Oncology. 2014;32(13):1365-83.

Senkus E, Kyriakides S, Ohno S et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2015;26 Suppl 5:v8-30. 

published: Sun, 23/10/2016 - 20:33
Previous Next
  • Contact Us
  • Copyright
  • Disclaimer
  • Privacy policy
Copyright © 2021 - Cancer Australia